BioHealth News
U.S. FDA Grants Theradaptive IDE Approval For Phase I/II Clinical Trials
Global study will assess the safety and efficacy of the company's lead spinal fusion product, OsteoAdapt SP FREDERICK, Md., Feb. 1, 2024 /PRNewswire/ -- Theradaptive, the market…
Read More
BioBuzz: Virginia Bio-Connect – The Success of Virginia’s First Statewide Collaborative Life Sciences Initiative
By Jelena Ivanjac | January 30, 2024 - The end of 2023 marked the completion of Virginia’s first statewide life sciences initiative, Virginia Bio-Connect, which started in April…
Read More
Baltimore’s LifeSprout Enters into Licensing Agreement with Boyang Trading to Develop and Commercialize Next-Generation Lumina™ Dermal Filler in Greater China
BALTIMORE, Jan. 31, 2024 /PRNewswire/ -- LifeSprout, a privately held regenerative medicine company founded with technology licensed from Johns Hopkins University, today announced it has entered…
Read More
GEN: Top 10 Biopharma Takeover Targets of 2024
By Alex Philippidis - February 1, 2024 - Viewed simply by numbers of merger and acquisition (M&A) deals, 2023 was a down year: 1,078 biotech companies found buyers…
Read More
Deadline Approaching: Apply to Be Part of the Maryland Delegation at BIO 2024
The Maryland Department of Commerce invites companies to seize the opportunity to join the Maryland delegation at the BIO International Convention in San Diego,…
Read More
FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech’s NT-I7 for Advanced Pancreatic Cancer Treatment
ROCKVILLE, Md., Jan. 30, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has…
Read More
Infinity Bio Launches Next-Generation Antibody Profiling Platform Utilizing MIPSA Technology
BALTIMORE--(BUSINESS WIRE)--Infinity Bio, Inc. announces its new antibody profiling platform, leveraging Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology. This platform offers unparalleled depth…
Read More
Revolo Biotherapeutics Receives Orphan Drug Designation from the U.S. FDA for its First-in-Class Peptide as a Potential Treatment for Eosinophilic Esophagitis
GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset…
Read More
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
ROCKVILLE, Md. and ST. LOUIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling platform…
Read More
Calling all MedTech innovators: Up to $100,000 in federal grants to be awarded
Application deadline is Feb. 15 for the pandemic network edition of “Make Your Medical Device Pitch for Kids!™ WASHINGTON, Jan. 29, 2024 (GLOBE NEWSWIRE)…
Read More
The Daily Record: New Johns Hopkins institute aims to make Baltimore an AI hub
Johns Hopkins University has launched an ambitious endeavor that the school’s leaders say will make Baltimore a hub of the booming artificial intelligence industry.…
Read More
PQE Group: 100+M€ In Revenues, Expansion In Emerging Markets and Business Lines
Florence, Jan. 26, 2024 – PQE Group, the renowned Life Science consulting powerhouse, concludes the fiscal year 2023 with a 10% growth and an…
Read More
First Patient Enrolled in Rockville’s Rise Therapeutics’ Rheumatoid Arthritis Clinical Trial
ROCKVILLE, Md., Jan. 29, 2024 /PRNewswire/ -- Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, today announced that it has enrolled its first…
Read More
QIAGEN announces partnership with Penn State University to advance microbiome sciences
Germantown, Maryland, and State College, Pennsylvania, Jan. 25, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a first-in-kind collaboration…
Read More
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
ROCKVILLE, Md., and SYDNEY, Australia, Jan. 23, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform…
Read More